The FDA made several approvals this week, including converting Tivdak’s accelerated approval to full approval for cervical cancer and approvals for a high-concentration formulation of Cyltezo, Xolremdi for an ultra rare immune disorder and Libervant Film for epilepsy in young children.
Health plans that use Optum Rx as their pharmacy benefit manager (PBM) will be allowed to tier their coverage of GLP-1s and still receive rebates under an agreement the PBM has reached with the manufacturers, says the PBM president. Optum officials said later that the negotiations were still ongoing,
The University of Michigan National Poll on Healthy Aging recently conducted the survey focusing on the concerns of adults aged 50 and above regarding various health-related issues in their communities.
At 12 months, the rate of IBD-related surgeries for the monitored group was 1% versus 7% for the control group.
Rapidly progressing interstitial lung disease in anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is known for its high death rate because it worsens quickly and causes breathing difficulties within three months of initial lung symptoms. However, there isn't much information about the timing between the diagnosis of ILD and MDA5 antibody-positive DM because most research focuses on either the frequency or the death rates rather than the timing of onset.
The retired four-start Navy admiral shared lessons learned from his training as a Navy SEAL and other parts of his life in his keynote address.
Cost and lack of access were two of the most common reasons given in new survey.
Optum and Takeda executives discuss their efforts to collaborate on implementing a value-based care for people with inflammatory bowel disease.
Company officials said a challenging reimbursement environment and escalating operating costs created a lack of profitability for the business.
In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about the disappointment surrounding the uptake of Humira biosimilars.
In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about whether or not she favors ending interchangeability designation for biosimilars.
GLP-1s, artificial intelligence and the Inflation Reduction Act are among the topics featured in the education sessions of the specialty pharmacy meeting in Las Vegas. The keynote speaker is William McRaven, a retired four-star admiral and former chancellor of the University of Texas system.
Lack of health insurance and not having a healthcare provider are two of the biggest factors that contribute to skipping a mammogram.
These programs aim to enhance the recruitment, training and retention of direct care workers who deliver vital home and community-based services to older adults and individuals with disabilities.
Gregory P. Brown, J.D., partner at Hill Ward Henderson, a law firm based in Tampa, talked about potential upcoming complications for healthcare employers and employees.
These awards cover research on a variety of crucial health areas including asthma, heart failure, migraine prevention and more.
Genes may help identify which cases of ductal carcinoma in situ are most likely to become invasive breast cancer.
UnitedHealth has found 22 screenshots, allegedly from Change Healthcare files, that were posted for about a week on the dark web. Some of these contained personal health information. The extent of data release is not yet known.
It is somewhat mind-boggling in 2024 that more than one-third of pharma organizations still rely on manual entry of data into Excel spreadsheets to track duplicate discounts that can cost millions of dollars a year in lost revenue
Five facts based off of findings on women's health.
Results published in the journal Ophthalmology find no risk reduction from daily one-gram capsules of omega-3 fatty acids.
Leaders at UC Davis Health created an emerging therapies committee to review and prepare for the wave of treatments that cost millions of dollars.
Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.
This decision may lead to faster approval of new treatments for multiple myeloma.
The executive order was created to acknowledge the challenges faced by families in accessing affordable, high-quality care, mainly due to the gap between costs and what families can afford.
Andel, principal of CommonHealth Solutions LLC, weighed in on potential strategies and challenges for Part D plans in navigating medication formulary limitations during catastrophic coverage phases in this second part of a two-part video series.
